StockData
Bionano Genomics, Inc. logo

Bionano Genomics, Inc. (BNGO) shareholders

BNGONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3083% below fair value
$0.95+0.01 (+1.29%)

Close on Nov 17, 2026Market cap $11.21MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
6.0%
1M of 12M shares
Institutional holders
33
8 new, 6 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $9.72K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
CVI Investments, Inc.
Joint filing with Heights Capital Management, Inc. (9.90%)
1,307,1359.90%13G (passive) amendmentJun 30, 2026
AIGH Capital Management LLC
Joint filing with Orin Hirschman (9.90%)
1,165,0009.90%13G (passive)Sep 30, 2026
Heights Capital Management, Inc.
Joint filing with CVI Investments, Inc. (9.90%)
1,129,4119.90%13G (passive) amendmentDec 31, 2025
Easton Jeff
Joint filing with Lind Global Fund III LP (9.35%), Lind Global Partners III LLC (9.35%)
1,050,0009.35%13G (passive) amendmentDec 31, 2025
Jeff Easton
Joint filing with Lind Global Fund III LP (9.90%), Lind Global Partners III LLC (9.90%)
1,005,9619.90%13G (passive)Sep 17, 2025
Waqas Khatri
Joint filing with Ayrton Capital LLC (9.99%), Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (9.99%)
528,2459.99%13G (passive)Sep 30, 2025
Lincoln Alternative Strategies LLC525,0005.42%13G (passive)Sep 17, 2025
Lind Global Partners III LLC
Joint filing with Lind Global Fund III LP (9.90%), Easton Jeff (9.90%)
514,3389.90%13G (passive) amendmentSep 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of BNGOValueChange% of portfolio
Gsa Capital Partners Llp150,2841.28%$170.00K−203,0790.01%
Carret Asset Management, LLC125,0001.06%$141.25K+55,0000.01%
Geode Capital Management, LLC89,9930.76%$101.69K−77,5400.00%
Vanguard Capital Management LLC82,3880.70%$93.10K+14,2790.00%
Vanguard Fiduciary Trust Co51,5780.44%$58.28K–0.00%
Renaissance Technologies LLC51,1000.43%$57.74K+2,4000.00%
Jane Street Group, LLC35,7280.30%$40.37KNew0.00%
Prudential Financial Inc31,6000.27%$35.71K+3,6000.00%
Northern Trust Corp24,5610.21%$27.75K+4,0420.00%
XTX Topco Ltd16,2950.14%$18.41KNew0.00%
Engineers Gate Manager LP11,9880.10%$13.55K+1350.00%
Hrt Financial LP11,7400.10%$13.00KNew0.00%
BlackRock, Inc.9,9370.08%$11.23K–0.00%
Osaic Holdings, Inc.7,8090.07%$8.82K+1,0070.00%
Tower Research Capital LLC (TRC)5,2280.04%$5.91KNew0.00%
Morgan Stanley1,0370.01%$1.17K+1100.00%
Concord Wealth Partners1,0000.01%$1.13KNew0.00%
Group One Trading, L.P.9570.01%$1.08K–0.00%
UBS Group AG8120.01%$918+7960.00%
SBI Securities Co., Ltd.2460.00%$278+120.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026331M6.0%8 / 112 / 60M0M
Q1 2026311M7.4%9 / 94 / 80M0M
Q4 2025311M7.5%9 / 59 / 81M0M
Q3 2025310M2.1%8 / 67 / 50M0M
Q2 2025280M0.9%5 / 76 / 60M0M
Q1 2025300M0.9%28 / 10 / 30M0M
Q4 202450M0.0%5 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

4 funds held BNGO in Q2 2026, 39% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of BNGOValue% of fundAs of
Fidelity Extended Market Index Fund113,5640.96%$140.82K0.00%May 31, 2026
Vanguard Extended Market Index Fund82,3880.70%$93.10K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund11,4700.10%$14.22K0.00%May 31, 2026
Fidelity Total Market Index Fund2,7690.02%$3.43K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Albert LudererInterim Chief Executive, Director8,0000.07%Sep 9, 2026
R. Erik HolmlinPRESIDENT AND CEO, Director1,6650.01%Feb 18, 2026
Jonathan V. DixonGeneral Counsel2390.00%Aug 5, 2026
Mark AdamchakPrincipal Accounting Officer2530.00%Aug 5, 2026
Alex Reid HastieChief Scientific Officer630.00%Aug 5, 2026
Mark OldakowskiChief Operating Officer8680.01%Aug 5, 2026
Alka ChaubeyCHIEF MEDICAL OFFICER6200.01%Jun 3, 2026
Aleksandar RajkovicDirector0–May 14, 2026
Kristiina Vuori MDDirector0–May 14, 2026
Christopher J. TwomeyDirector74,5000.63%May 14, 2026
David L. BarkerDirector58,3640.50%May 14, 2026
Yvonne LinneyDirector0–May 14, 2026
Hannah MamuszkaDirector65,7890.56%Jun 12, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Albert Luderer
Interim Chief Executive, Director
Sep 4, 2026Buy+4,000$1.21$4.84K8,000
Albert Luderer
Interim Chief Executive, Director
Aug 21, 2026Buy+4,000$1.22$4.88K4,000
Alka Chaubey
CHIEF MEDICAL OFFICER
Jun 3, 2026Tax withholding−24$1.30$31620
Mark Adamchak
Principal Accounting Officer
Jun 3, 2026Tax withholding−7$1.30$9253
Jonathan V. Dixon
GENERAL COUNSEL
Jun 3, 2026Tax withholding−24$1.30$31239
Mark Oldakowski
CHIEF OPERATING OFFICER
Jun 3, 2026Tax withholding−27$1.30$35868
Alka Chaubey
CHIEF MEDICAL OFFICER
Feb 17, 2026Tax withholding−18$1.10$20644
Mark Oldakowski
CHIEF OPERATING OFFICER
Feb 17, 2026Tax withholding−20$1.10$22895
Mark Adamchak
Principal Accounting Officer
Feb 17, 2026Tax withholding−3$1.10$3260
R. Erik Holmlin
PRESIDENT AND CEO, Director
Feb 17, 2026Tax withholding−51$1.10$561,657
Jonathan V. Dixon
GENERAL COUNSEL
Feb 17, 2026Tax withholding−6$1.10$7263
Mark Oldakowski
Chief Operating Officer
Sep 11, 2025Tax withholding−59$4.06$240915
Alka Chaubey
Chief Medical Officer
Sep 11, 2025Tax withholding−51$4.06$207662
Mark Oldakowski
Chief Operating Officer
Sep 11, 2025Tax withholding−59$4.06$240915
Mark Oldakowski
Chief Operating Officer
Jun 3, 2025Tax withholding−27$3.69$100974
R. Erik Holmlin
President and CEO, Director
Jun 3, 2025Tax withholding−75$3.69$2771,708
Alka Chaubey
Chief Medical Officer
Jun 3, 2025Tax withholding−24$3.69$89713
Jonathan V. Dixon
General Counsel
Jun 3, 2025Tax withholding−25$3.69$92269
Mark Adamchak
Principal Accounting Officer
Jun 3, 2025Tax withholding−7$3.69$26263
R. Erik Holmlin
President and CEO, Director
Mar 14, 2025Tax withholding−198$3.47$6871,783
Mark Oldakowski
Chief Operating Officer
Feb 15, 2025Tax withholding−20$5.73$1151,001
Alka Chaubey
Chief Medical Officer
Feb 15, 2025Tax withholding−18$5.73$103737
Jonathan V. Dixon
General Counsel
Feb 15, 2025Tax withholding−6$5.73$34294
Mark Adamchak
Principal Accounting Officer
Feb 15, 2025Tax withholding−4$5.73$23270
R. Erik Holmlin
President and CEO, Director
Feb 15, 2025Tax withholding−51$5.73$2921,981
Alka Chaubey
Chief Medical Officer
Sep 11, 2024Tax withholding−3,075$0.48$1.48K45,323
Mark Oldakowski
Chief Operating Officer
Sep 11, 2024Tax withholding−3,568$0.48$1.71K61,283
Mark Oldakowski
CHIEF OPERATING OFFICER
Jun 3, 2024Award+16,000––64,698
Jonathan V. Dixon
GENERAL COUNSEL
Jun 3, 2024Award+14,500––18,025
Alka Chaubey
CHIEF MEDICAL OFFICER
Jun 3, 2024Award+16,000––48,245
Gulsen Kama
Chief Financial Officer
Jun 3, 2024Award+16,000––16,000
R. Erik Holmlin
PRESIDENT AND CEO, Director
Jun 3, 2024Award+44,000––121,813
R. Erik Holmlin
PRESIDENT AND CEO, Director
Feb 15, 2024Tax withholding−3,073$1.27$3.90K77,663
Jonathan V. Dixon
GENERAL COUNSEL
Feb 15, 2024Tax withholding−402$1.27$5113,525
Alka Chaubey
CHIEF MEDICAL OFFICER
Feb 15, 2024Tax withholding−1,081$1.27$1.37K31,487
Mark Oldakowski
CHIEF OPERATING OFFICER
Feb 15, 2024Tax withholding−1,229$1.27$1.56K48,644
Alka Chaubey
Chief Medical Officer
Sep 18, 2023Award+20,000––144,794
Mark Oldakowski
Chief Operating Officer
Sep 18, 2023Award+20,000––317,842
Hannah Mamuszka
Director
Jun 13, 2023Buy+65,789$0.76$50.00K65,789
R. Erik Holmlin
President and CEO, Director
May 16, 2023Buy+15,000$0.64$9.60K806,474
Mark Oldakowski
Chief Operating Officer
May 12, 2023Tax withholding−41,496$0.66$27.39K297,842
R. Erik Holmlin
President and CEO, Director
May 12, 2023Tax withholding−50,141$0.66$33.09K791,474
Christopher P. Stewart
Chief Financial Officer
May 12, 2023Buy+50,000$0.67$33.50K281,373
Christopher P. Stewart
Chief Financial Officer
Feb 15, 2023Award+105,000––231,373
Alka Chaubey
Chief Medical Officer
Feb 15, 2023Award+120,000––124,794
R. Erik Holmlin
President and CEO, Director
Feb 15, 2023Award+300,000––841,615
Mark Oldakowski
Chief Operating Officer
Feb 15, 2023Award+120,000––339,338
Yvonne Linney
Director
Aug 15, 2022Sale−20,000$3.62$72.40K0
Yvonne Linney
Director
Aug 15, 2022Option exercise+20,000$0.38$7.60K20,000
David L. Barker
Director
Jul 7, 2022Option exercise+44,470$0.51$22.68K58,364
David L. Barker
Director
May 16, 2022Buy+10,000$1.60$16.00K13,894
Christopher P. Stewart
Chief Financial Officer
May 13, 2022Option exercise+60,000$0.56$33.60K121,579
Mark Oldakowski
Chief Operating Officer
May 12, 2022Tax withholding−41,496$1.41$58.51K216,669
R. Erik Holmlin
President and CEO, Director
May 12, 2022Tax withholding−50,141$1.41$70.70K538,556
Soheil Shams
Chief Informatics Officer
Dec 30, 2021Gift−318,899––5,006,479
R. Erik Holmlin
President and CEO, Director
Nov 29, 2021Buy+2,675$3.99$10.67K4,875
R. Erik Holmlin
President and CEO, Director
Nov 29, 2021Buy+2,200$3.99$8.78K2,200
R. Erik Holmlin
President and CEO, Director
Nov 29, 2021Buy+150$3.98$5975,025
Christopher P. Stewart
Chief Financial Officer
Nov 19, 2021Option exercise+22,500$0.56$12.60K55,500
Soheil Shams
Chief Informatics Officer
Oct 18, 2021Award+5,325,378––5,325,378

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
12.00%
1M shares short
Days to cover
7.4
At 0M shares a day
Change since last report
+2.0%
From 1M shares
Short volume, 20 days
49.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Bionano Genomics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 384,527 shares on Sep 16, 2026 over the last 90 days.

See a number that looks wrong?